Liver Transplantation:
Information
on allocation of livers, recurrent HCV after transplantation, treatment of HCV
before and after liver transplantation, post transplantation disease progression,
and long term outcomes after liver transplantation
·
Allocation/General
o
611. Development of a UK Score
for Patients with End-stage Liver Disease
·
Allocation/MELD
o
552. MELD-Na is superior to
other organ allocation systems (updated
o
564. Implementation of a liver
allocation system based on MELD score in three transplant centers of the same
city. Can the score differences be solved? (updated
o
603. Long Term Outcomes Of
Liver Transplantation In A High-MELD Cohort
·
General
o
521. Chronic hepatitis E : a
new entity in organ transplant patients (updated
o
527. Comparison between
hepatic elasticity measurements (Fibroscan®) and liver biopsy in patients transplanted
for HCV cirrhosis (updated
o
533. High Prevalence of
Glomerulonephritis in Patients with End-stage HCV-induced Cirrhosis (updated
o
561. Combined liver heart
transplantation in the United States (updated
o
576. Sexual dysfunction before
and after liver transplantation (LT)
o
589. Pre-transplant variables
predict qualify of life in liver transplant recipients
o
602. The Readability of Health
Education Materials for Liver Transplant Patients (updated
o
621. Use of
Donation-after-Cardiac-Death (DCD) Donors for Combined Liver and Kidney
Transplantation
·
Liver Cancer
o
585. Trends in Liver
Transplantation for Hepatocellular Carcinoma in the United States
·
Living Liver Donors
o
554. Graft Survival after
Living Donor or Cadaveric Liver transplantation: An Analysis Stratified by
Donor Risk (updated
o
617. Successful Algorithm for
Selective Liver Biopsy in the Right Lobe Liver Donor (RLD)
o
618. High MELD scores do not
predict one-year survival rate of patients with a small-for-size graft in adult
living donor liver trasplantation (updated
·
Post Transplant
o
522. Post-Liver Transplant
Survival in Hepatitis C Patients is Improving, Not Declining (updated
o
520. Evaluation of Week 12
Response on SVR in HCV Post Transplant Patients Undergoing PEG/RBV Therapy (updated
o
531. Multicenter randomized
trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin
followed by ribavirin alone after liver transplantation: Final report (updated
o
532. Hepatitis C Virus (HCV)
Infection is a Protective Factor for Hepatitis B Virus Reactivation (HBVr)
After Receiving Hepatitis B Core Positive (HBcAb+) Donors for Liver
Transplantation (LT) (updated November 4, 2007)
o
545. Predicting Cardiovascular
Events After Liver Transplantation (updated
o
546. Transplantation Trends in
Recipients Over the age of 65 (updated
o
558. Smoking related morbidity
and mortality post liver transplantation (updated
o
566. Outcomes of
Transplantation with previously Refused Donor Livers in Region 8 (updated
o
593. GB Virus-C Infection is
Associated with Better 10-Year-Survival of Liver Transplant Recipients (updated
o
598. Hepatocellular Carcinoma (HCC)
in Patients with HCV versus non-HCV Cirrhosis: Graft and Patient Survival after
Liver Transplantation (LT) in Pre-MELD and MELD Era (updated
o
603. Long Term Outcomes Of Liver
Transplantation In A High-MELD Cohort
o
Recurrence
§
536.
Serum Levels Of Fibrosis Progression Biomarkers Measured Early After LT Are
Associated To Severe HCV Recurrence (updated
§
540.
Fibrosis Progression on Protocol Liver Biopsies In Patients With Recurrent HCV
Following Liver Transplantation (updated
§
544. Response of fibrosing
cholestatic recurrent hepatitis C following liver transplantation to
combination interferon/ribavirin therapy (updated
§
547.
The effect of disease recurrence on graft survival following orthotopic liver
transplantation (updated
§
553.
Long term results of a randomized trial of tacrolimus monotherapy versus triple
therapy in HCV cirrhosis liver transplant recipients. (updated